From Lab to Market: The Golden Era of the Synthetic Biology Billion-Dollar Industry
VCBeat
Internet Medical Health Media
Synthetic biology is hailed as the “Third Biotechnology Revolution.” It is not only a cutting-edge technology but also represents a fundamental shift in the paradigm of biomanufacturing. From pharmaceuticals and vaccines to food additives, and from green materials to environmental remediation, synthetic biology technologies are demonstrating significant application potential and transformative power across multiple fields.
Currently, the industry is exhibiting two distinct trends: first, the deep integration of technological pathways, where AI and data science are reshaping the “design-build-test-learn” R&D loop, making cell factory development more intelligent; second, the accelerated synergy within the industrial ecosystem, with capital, enterprises, and research institutions forming a more tightly coupled network to jointly drive the translation of technologies from the laboratory to industrial application.
However, this sector also faces multiple challenges, including technological engineering, scaled-up production, and cost control. Key issues that industry participants must address include how to effectively translate advanced technologies into commercial value, how to build sustainable business models, and how to identify the optimal development pathways across diverse application scenarios.
Against this backdrop, the transaction session of "China's Innovative Medical Asset Living Room," co-hosted by VCBeat and Wei Jieyao, was held on Thursday, January 22 at 15:00."Roundtable Discussion Episode 13, featuring"Zhou Lixin, Healthcare Partner at Kairui Capital、Xiong Xiaochao, General Manager of Weichuang Shengcheng; Yang Junsheng, Executive Director of Fuyuan InvestmentIIIguests centered aroundFrom Technical Experiments to Commercial Implementation: The Golden Age of the Hundred-Billion-Yuan Synthetic Biology SectorThrough open-ended discussions, we provide buy-side investors with actionable trading logic and insights into frontier sector allocation, establishing a “strategic think tank” for healthcare innovation asset transactions. This empowers buy-side firms to efficiently capture high-quality deal opportunities, bridging China’s healthcare innovation assets with global buyers.
Host: Zhou Lixin
Partner, Healthcare, Kailian Capital
EMBA, CEIBS. Led the medical investment and research team at Kailian Capital to invest in industry-leading projects such as Sangon Biotech, Tsingke Biological Technology, iCellar, and Zhongyuan Yuze. Previously served at Nanjing General Hospital of the Nanjing Military Command, Euroimmun, and Thermo Fisher Scientific, and founded two startups, accumulating over fifteen years of industry experience.
Guest: Xiong Xiaochao
General Manager of MicroPort Genesis
Previously served as an Assistant Professor at a U.S. state university and Chief Technology Officer of a startup. Upon returning to China, he was selected for the Shanghai Overseas High-Level Talent Program and the “Pujiang” Talent Program, and led the company in establishing an integrated bio-based product R&D and industrial chain encompassing cell factory construction, high-throughput screening, metabolic network data-driven approaches, and precision fermentation.
Guest: Yang Junsheng
Executive Director, Fuyuan Investment
Graduated from Fudan University’s eight-year clinical medicine program and holds an MBA from Cornell University. Previously served as a resident physician at Huashan Hospital and as Vice President of Jifeng Capital, with a focus on investment in medical devices and biomanufacturing.
China Innovative Healthcare Assets Lounge - Transaction Roundtable
"China Innovative Healthcare Asset Lounge" is an online live-streaming program by VCBeat, positioned around the core mission of "connecting China's healthcare innovation assets with global buyers." It focuses on high-quality asset transactions in fields such as innovative drugs, high-end medical devices, and digital health, aiming to build a professional platform for "showcasing, communicating, and matchmaking" for strategic, financial, and industrial buyer groups. With the goal of "unlocking the value of China's innovative assets and facilitating efficient transactions," the program helps buyer groups seize opportunities in high-quality assets through precise supply-demand matching, analysis of transaction logic, and sharing of practical experience, while also promoting the conversion and retention of local innovative assets, thereby supporting the ecosystem development of the Global Life and Health Innovation Asset Buyer Alliance.
As a flagship segment of the Online Living Room, “Deal Roundtable” delves into hot topics surrounding the transaction of innovative healthcare assets. Since its launch, it has successfully hosted twelve sessions, inviting over 60 strategic innovation heads from multinational corporations (MNCs), corporate venture capital leaders, and fund investment executives to share their insights. With an average live viewership exceeding 5,000 per episode, it has become a highly influential “hub for intelligence on innovative asset transactions” within the industry.
Scan the QR code to reserve your spot for the live broadcast.
Submissions Open for the 2026 Future Healthcare Top 100 Selection!
The 2026 Top 100 Future Healthcare Companies selection anchors on the core direction of “Innovation, Transaction, and Empowerment in China’s Healthcare Industry,” achieving a comprehensive upgrade of the evaluation system. This edition features two core components: the 2026 Top 100 Future Healthcare Companies List and the 2026 Top 100 Future Healthcare Companies Awards.
Scan the QR code to learn more about application details.